If the study product does not make modifications to CXCR4 for safety reasons, then will this product not work on someone whose trofile comes back as CXCR4-type HIV?

The AGT103-T reduces CCR5 levels but, as noted in the question, does not change CXCR4 levels. Unlike other products that only impact CCR5, our product also attacks conserved regions of the HIV genome. The combination of CCR5 decrease and attack on HIV RNA gives very high protection against CCR5-tropic HIV (>97% in some assays) and good levels of protection (>90%) against CXCR4-tropic HIV. This is a valid concern and we anticipated the problem during the design phase of product development.